Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 12,244 matching trials from the live ClinicalTrials.gov search.
Conditions
Ulcer Venous, Wound Heal
Interventions
InnovaMatrix® AC Sterilized, Porcine Placental Extracellular Matrix (ECM)
Device
Lead sponsor
ConvaTec Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Active, not recruiting No phase listed Observational

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401
Conditions
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
147
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
Conditions
Myeloma-Multiple, Myeloma, Plasma-Cell
Interventions
Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 73 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Neural Disorders

NCT02761707
Conditions
Parkinson's Disease, Alzheimer's Disease, Progressive Supranuclear Palsy, Essential Tremor, Multiple System Atrophy, Drug Induced Parkinson's Disease, Diffuse Lewy Body Disease, Myasthenia Gravis, Spinal Cord Injuries
Interventions
Electrical Brainstem Responses, Olfactory Tests, Visual Deprivation, Peripheral Nerve Stimulation
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Feasibility Study of Metformin Therapy in ADPKD

NCT02903511
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Metformin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
Interventions
Backward Walking Training, Forward Walking Training
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Completed No phase listed Observational

Characterization of Angelman Syndrome

NCT00296764
Conditions
Angelman Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 60 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Conditions
Alagille Syndrome
Interventions
LUM001, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Months to 18 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more
Conditions
Multiple Myeloma
Interventions
Lenalidomide plus Melphalan during autologous stem cell transplantation, Lenalidomide maintenance
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
tipifarnib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hepatitis C
Interventions
IMO-2125, Saline placebo
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Aurora, Colorado • Marietta, Georgia • Novi, Michigan + 3 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls

NCT01523964
Conditions
Duchenne Muscular Dystrophy
Interventions
Testing with EIM
Other
Lead sponsor
Dart Therapeutics. LLC
Other
Eligibility
3 Years to 12 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Conditions
Gout
Interventions
D-0120, Allopurinol
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Plantation, Florida • Evergreen Park, Illinois + 16 more
Conditions
Multiple Sclerosis
Interventions
fampridine, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 70 Years
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
17
States / cities
Cullman, Alabama • Phoenix, Arizona • San Diego, California + 12 more
Conditions
Obesity, Overweight or Obesity
Interventions
MET097, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Anaheim, California • Hollywood, Florida
Conditions
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Migraine Headaches
Interventions
Botulinum Toxin Type A, Surgery, Daily headache diary, Migraine Disability Assessment Test (MIDAS), Migraine Work and Productivity Loss Questionnaire (MWPLQ), Migraine-Specific Quality of Life Questionnaire (MSQ)
Drug · Procedure · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
San Francisco, California • Olathe, Kansas • Boston, Massachusetts + 3 more
Conditions
Dystonia, Focal, Task-specific
Interventions
rTMS, Sham rTMS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota